Luoxin Pharmaceutical and HK inno.N of South Korea join hands again, aiming at the US$2 billion Chinese PPI injection market

P-CAB, as a new type of acid-suppressing drug, makes up for the "pain points" of traditional acid-suppressing drugs PPI, which requires acid activation, short half-life and insufficient acid suppression, resulting in low mucosal healing rate

Tigolasan injection is mainly used for the treatment of gastroesophageal reflux, upper gastrointestinal bleeding and prevention of stress gastric mucosal injury, etc.

According to IQVIA data, China's proton pump inhibitor (PPI) drug market in 2020 will be approximately US$3 billion, ranking second in the world after the United States, of which the injection market size is approximately US$2 billion and approximately RMB 12.

The cooperation between Luoxin Pharmaceutical and HK inno.

According to IQVIA data, the global sales of ticolax tablets in 2020 will be US$50 million (calculated at the ex-factory price), an increase of 106% year-on-year

In June 2017, Luoxin's LXI-15028 project obtained clinical trial approval.

The cooperation between China and South Korea on tegoraxan injection products further demonstrates Luoxin Pharmaceutical's R&D and commercialization advantages in the gastrointestinal field